CurTec expands US manufacturing and warehouse capacity in South Carolina

CurTec USA is investing $10 million to expand its Westminster, South Carolina operations, creating 10 new jobs. The project will increase warehouse and production capacity and broaden the range manufactured in the United States.

The expansion will add approximately 27,300 square feet and more than 2,000 pallet positions. Groundbreaking is planned for October 2026, with completion expected in Q2 2027.

CurTec is expanding its manufacturing operations in Westminster, S.C. with a new warehouse and additional production capacity.

CurTec is expanding its manufacturing operations in Westminster, S.C. with a new warehouse and additional production capacity.

“When we opened Westminster in 2023, our goal was to get closer to North American customers and create a platform for growth,” says Bart van Berkel, CEO of CurTec. “This expansion strengthens local production, inventory and supply reliability while broadening the range we manufacture in the United States.”

Expanding local production

A new blow molding line will significantly increase capacity and extend local production to smaller packaging sizes. CurTec plans to produce 6- and 10-liter Click Pack pails in Westminster before year-end, followed by smaller Wide Neck Drums in 2027.

“Expanding production and warehousing together gives us greater flexibility to respond to customer demand,” says Roy Kuipers, Operations Directorat CurTec. “It also allows us to manufacture more of our portfolio locally.”

“Westminster was designed for future growth,” says Martin Lamar, Site Director USA. “We are now adding capacity and capability while growing our local team.”

“It is another ‘Top Shelf for Business’ day in Oconee County,” says Jamie Gilbert, President and CEO of the Oconee Economic Alliance. “Just three years after opening the facility, this investment reflects CurTec’s confidence in our workforce and business climate. We value our partnership and look forward to CurTec’s continued growth in our community.”

About CurTec

CurTec manufactures high-performance packaging for life sciences and fine chemicals.

CurTec supports life sciences and fine chemicals companies with high-performance packaging for the safe handling and containment of critical materials. CurTec has GMP-certified production facilities in Westminster, South Carolina, and Rijen, the Netherlands.

Source link

Alvotech Wins FDA Approval to Expand U.S. Manufacturing Capacity for SIMLANDI at Reykjavik Facility

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

REYKJAVIK, Iceland (October 5, 2026)

– Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company’s Reykjavik facility. This approval further confirms resolution of inspection-related matters at the Reykjavik site.

“This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility,” said Lisa Graver, Chief Executive Officer of Alvotech. “The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market. It also reflects the significant progress our teams have made in strengthening quality systems and manufacturing operations at the site.”

The second suite, DSM2, supports the complete drug substance manufacturing process, including cell culture and purification, and doubles Alvotech’s manufacturing capacity available to support U.S. supply. DSM2 is already approved for the manufacture of commercial drug substance for European markets, including for AVT02, AVT03, and AVT05. Following the FDA approval, Alvotech can now manufacture AVT02 drug substance for U.S. commercial supply in either DSM1 or DSM2, providing additional capacity and greater flexibility across its manufacturing operations.

The approval follows the FDA’s July 2026 closure of its most recent inspection of the Reykjavik facility with a Voluntary Action Indicated (VAI) classification. Alvotech therefore expects the FDA to be able to take action on other pending applications associated with the facility according to their respective goal dates. These include BLAs for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), AVT03, Alvotech’s proposed biosimilar to Prolia® and Xgeva® (denosumab) and AVT16/AVT80, Alvotech’s proposed biosimilars to Entyvio® (vedolizumab). Each application remains subject to the FDA’s individual review and regulatory decision.

About AVT02 / SIMLANDI® (adalimumab-ryvk)

AVT02 is a monoclonal antibody approved as a biosimilar to Humira® (adalimumab) in more than 50 countries globally, including the United States, Europe, Canada and Australia. It is currently marketed in the U.S. as SIMLANDI® and under private label, in Europe as HUKYNDRA®, in Canada as SIMLANDI® and in Australia as ADALACIP®. Teva Pharmaceuticals is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI® in the United States, while Alvotech is responsible for development and manufacturing.

For further information, contact:

Media

Benedikt Stefansson

Sarah MacLeod


[email protected]

Investors

Dr. Balaji V Prasad

Benedikt Stefansson

Mikaela Vilchez


[email protected]

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our

website

or follow us on social media on

LinkedIn

,

Facebook

,

Instagram

, and

YouTube

.

Use of trademarks

Third party trademarks are the property of their respective owners.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Source link

Attalon Invests Nearly $13 Million to Expand U.S. Sapphire Manufacturing Capacity

Attalon Invests Nearly $13 Million to Expand U.S. Sapphire Manufacturing Capacity

Investment in Murrieta, California, expands domestic production of advanced optical materials supporting growing demand across EO/IR and next-generation defense systems

Attalon, a leading U.S. aerospace and defense technology company, today announced a nearly $13 million investment to expand sapphire manufacturing capacity at its Murrieta, California, operation, strengthening domestic production of a critical optical material used across demanding electro-optical and infrared defense applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929509193/en/

Sapphire produced at Attalon’s Murrieta, California, facility supports advanced optical systems for mission-critical defense applications. Attalon is investing nearly $13 million to expand domestic manufacturing capacity.

The investment comes as demand for high-performance optical materials continues to increase across advanced sensing, targeting, surveillance, missile and other mission-critical defense systems. By expanding its U.S.-based sapphire manufacturing capabilities, Attalon is increasing the production capacity, manufacturing readiness and technical capabilities required to support customers as these systems move toward greater production volumes.

“Sapphire is an enabling technology behind some of today’s most demanding defense systems, and ensuring we have the domestic capacity to produce it at scale is increasingly important,” said John Bergeron, Chief Executive Officer of Attalon. “This investment is about building that capacity here in the United States and ensuring our customers have a trusted manufacturing partner ready to grow alongside their programs.”

The investment builds on a longstanding effort to establish and sustain a domestic U.S. supply of defense-critical sapphire. More than seven years ago, Congressman Ken Calvert, now Chairman of the House Appropriations Subcommittee on Defense and representative for Murrieta, played an important role in supporting federal investment in the advanced technology and manufacturing capabilities required to establish Murrieta as a domestic source for high-performance sapphire.

That early government investment, coupled with sustained private-sector investment in the facility, helped build the technical expertise and U.S. manufacturing capability required to support demanding defense applications, including the F-35 program. Attalon’s nearly $13 million investment marks the next phase of that effort—expanding capacity, advancing manufacturing capabilities and strengthening a proven domestic supply of sapphire for current and next-generation defense systems.

Sapphire combines exceptional optical performance with the durability required for demanding defense environments. Its material properties make it particularly well suited for advanced EO/IR applications where optical performance, environmental resilience and reliability are essential to mission success.

“Our Murrieta team has built deep expertise in sapphire, from material development through production, and this investment allows us to translate that expertise into greater manufacturing scale,” said Anthony McBride, Vice President and General Manager of Precision Optics at Attalon. “We’re expanding the capabilities and infrastructure needed to increase throughput while maintaining the precision, consistency and reliability our customers depend on.”

The expansion is part of Attalon’s continued investment in the enabling technologies behind next-generation defense systems and its strategy of expanding U.S.-based manufacturing for mission-critical technologies. Across advanced optical materials, precision optics, optical coatings, directed energy and thermal technologies, the company is increasing domestic capacity in areas where manufacturing scale, reliability and supply-chain resilience are increasingly important to national security and the advanced defense platforms that depend on them.

About Attalon

Attalon is a leading U.S. aerospace and defense technology company engineering and manufacturing advanced lasers, precision optics, optical coatings, advanced materials and thermal technologies. With more than 500 employees across the United States, Attalon combines deep technical expertise with scalable domestic manufacturing to deliver mission-critical capabilities that strengthen the U.S. defense industrial base and support the modern warfighter.

Press Contact:

Valerie McKiernan

Vice President, Strategy & Communications

Valerie.McKiernan@atln.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260929509193/en/

Source link

Kentucky: How Ford is Rebuilding US Manufacturing Capacity

Key companies 

Ford

Headquarters: Michigan, US
CEO: Jim Farley

Ford is an international automotive manufacturer producing commercial trucks, passenger cars, utility vehicles and electric mobility solutions. Managing heavy stamping plants, engine facilities and vehicle assembly lines globally, the enterprise scales advanced industrial operations. 

General Motors

Headquarters: Michigan, US
CEO: Mary Barra

General Motors is a major automotive manufacturing enterprise operating vehicle assembly networks, stamping facilities and battery plants across North America. The business drives industrial production by scaling modular electric vehicle platforms, advancing autonomous driving integration and deploying automated assembly technology across its factories. 

Apple

Headquarters: California, US
CEO: John Ternus

Apple is an international technology enterprise designing and manufacturing consumer electronics, personal computer hardware and mobile devices. The corporation manages a vast global hardware supply chain, coordinating specialised component fabrication, precision tooling and high-volume assembly operations. 

Source link

US PV manufacturing: how much capacity will actually be online by 2030? 

US PV manufacturing: how much capacity will actually be online by 2030?  – PV Tech

Skip to content

Close

Previous

Next

Source link

Trump Pushes U.S. Defense Firms To Expand Arms Manufacturing Capacity

President Donald Trump is expected to call on top defense executives on Wednesday to ramp up weapons production and expand manufacturing capacity as conflicts in Ukraine and the Middle East put pressure on U.S. stockpiles and reveal weaknesses in the industrial base.

Trump will join a roundtable discussion at a two-day Defense and Innovation Summit hosted by Republican Senator Dave McCormick at the U.S. Army War College in Pennsylvania. The gathering brings together military officials, defense contractors, investors and technology leaders to discuss strengthening U.S. manufacturing and accelerating the delivery of advanced weapons systems.

Faster Innovation and Production

Trump’s appearance underscores a broader focus by the administration on defense production as prolonged conflicts have consumed large quantities of missiles, interceptors and other weapons, while highlighting the limits of the U.S. military supply chain and production capacity. Trump is expected to make several Pennsylvania-based defense investment announcements.

Joint Chiefs of Staff Chairman General Dan Caine urged defense companies on Tuesday to accelerate production and innovation, saying the military needs industry partners to help deliver capabilities faster as warfare evolves.

“What I need you to know, and I know this is simple for me to say, but hard to do, is to go faster. Please go faster. Think bolder,” Caine said.

Broader Industrial Strategy

For Trump, expanding defense manufacturing has become part of a wider economic strategy to revive U.S. industrial capacity, with the Pentagon increasingly viewed as a catalyst for factory investment, advanced manufacturing and domestic supply chains.

In late June, Trump met with munitions makers at the White House to urge the industry to move faster.

United States has supplied large quantities of weapons to allies while also using munitions in its own military operations, raising concerns about inventories of key air-defense and precision-guided weapons and increasing pressure on contractors to boost output. Soaring demand for rocket motors used to power missiles and other weapons has spurred new thinking about supply chains.

Seeking big returns, Silicon Valley-style startups are now taking on defense companies that have long dominated the industry, pulled into the competition by a need for production speed, high volume and lower costs. Legacy solid rocket motor makers Northrop Grumman and L3Harris say they have been pushing their own research and development to pull in new technologies like 3D printing and new mixing technologies.

Michael Duffey, who oversees buying for the Pentagon, told the summit audience that the department is using long-term procurement contracts to give defense companies the confidence to invest billions of dollars in expanding factories, citing roughly $20 billion in private investment tied to plans to boost production of Patriot missiles and other high-demand weapons.

“The global environment now demands that we produce at this scale, at this speed, at this volume,” he said.

(With inputs from Reuters)

Source link

Rolls-Royce starts Raynesway site expansion to double submarine reactor manufacturing capacity for UK and Australian programmes

Rolls-Royce Submarines has officially broken ground and started foundational work on a new manufacturing facility at its Raynesway site in Derby. The work forms part of a wider plan to double the size of the entire site.

The expansion will help meet increased demand from the UK and Australian Royal Navies for current and future submarine programmes. More than 100,000m2 of new manufacturing and office facilities will be built, creating 1,170 skilled roles across disciplines including manufacturing and engineering.

The ceremonial event brought together Minister of State for Defence Lord Coaker, Rolls-Royce Submarines President Abi Clayton and Commodore Alistair Moody, Director for Nuclear Propulsion at the Submarine Delivery Group. They dug the first ground together, reflecting the partnership behind the expansion and the significance of the programme.

During the visit, Lord Coaker also met Rolls-Royce nuclear welding apprentices who recently secured first, second, third and fourth place in the SkillWeld 26 East Midlands heats. Rolls-Royce said it was the first time all top-three places had been won by the same company.

SkillWeld is a national competition designed to showcase and benchmark trainee and apprentice welders. The achievement follows welding apprentice Jack Billingham being selected to represent Great Britain at the WorldSkills event in Japan.

Rolls-Royce announced in June 2023 that it planned to double the size of its Submarines site. The Raynesway facility designs and builds the nuclear reactors that power all Royal Navy submarines and helps maintain the UK’s continuous at sea nuclear deterrent.

Under the AUKUS partnership between Australia, the UK and the United States, Rolls-Royce will also provide reactors for future Australian SSN-AUKUS attack submarines. The expansion is intended to unlock additional manufacturing capacity and support the pace of submarine build programmes.

Abi Clayton, President – Rolls-Royce Submarines, said: “Breaking ground is a significant step forward in the critical growth of our business. This expansion will more than double the size of our manufacturing facility, strengthening our capability and demonstrating our ongoing commitment to the Defence Nuclear Enterprise.”

“Together with our trusted delivery partners, our commitment is to deliver this programme safely, efficiently and to the highest standards. This work will unlock much-needed manufacturing capacity on site, allowing us to enhance our delivery drumbeat to support the boat build programmes.”

Defence Minister Lord Coaker said: “The expansion of the Rolls-Royce site is a clear demonstration of the government’s commitment to the UK’s nuclear deterrent. Witnessing the manufacturing of the fifth SSSN-AUKUS reactor and the hundreds of apprentices in action was inspiring – seeing defence investment creating jobs, driving growth, and keeping the UK safe.”

Commodore Alistair Moody, Director for Nuclear Propulsion at the Submarine Delivery Group, said: “The ongoing expansion work at Raynesway demonstrates the shared commitment of the UK and Australian governments to meet the ambitious pace of our submarine build programmes. Together, we are building the foundations for delivery to defend our nations for decades to come.”

“The significant nuclear enterprise investment confirmed in the DIP reflects the UK’s unwavering commitment to maintaining and renewing our nuclear deterrent, a capability that has protected the UK and our allies for almost 60 years. Delivering this work is a National Endeavour and continues to drive growth, strengthen security and sustain tens-of-thousands of jobs across the UK.”

Rolls-Royce Submarines currently employs more than 5,500 people. It designs, manufactures and provides in-service support to the pressurised water reactors that power every submarine in the Royal Navy’s fleet.

The company is supporting the Astute and Dreadnought boat build programmes through delivery of reactor plant and associated components. This work is delivered by the UK MOD’s Defence Nuclear Enterprise as part of a national endeavour to sustain the nuclear deterrent.

Rolls-Royce also provides frontline support worldwide for reactor plant equipment from its Operations Centre in Derby. It supports submarines at the Barrow-in-Furness shipyard and at the naval bases at Devonport and Faslane, with technical specialists also working in Glasgow, Cardiff and Thurso.

Source link

Johnson & Johnson Raises U.S. Vision Manufacturing Capacity With More Than $1 Billion Jacksonville Investment

Johnson & Johnson announced an investment of more than $1 billion to expand its Vision operations in Jacksonville, Florida, strengthening the company’s U.S.-based manufacturing, packaging, and distribution capabilities for its ACUVUE-brand contact lenses.

The investment includes the construction of a new distribution facility and the addition of advanced manufacturing and packaging technologies designed to increase capacity and meet growing demand for the company’s contact lens products. The expansion is intended to support eye health solutions used by more than 40 million patients in the United States and globally.

The project is part of Johnson & Johnson’s previously announced $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029. Construction of the new Jacksonville facility is already underway, and the site is expected to become fully operational in 2028.

Johnson & Johnson said the expansion builds on its approximately $6 billion annual economic impact in Florida and supports continued growth for its Jacksonville operations. The company currently employs about 3,500 people in the area.

Jacksonville has served as a key center for the company’s vision business for more than 40 years. Since establishing operations there in 1981, Johnson & Johnson has expanded to more than 1.5 million square feet of manufacturing, research, distribution, and operations facilities. The company currently manufactures more than 1.7 billion ACUVUE contact lenses annually for U.S. patients.

Local, state, and federal officials said the investment will strengthen healthcare manufacturing capabilities, create jobs, and reinforce Northeast Florida’s role in the life sciences and advanced manufacturing sectors.

KEY QUOTES:

“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world. By further strengthening our Vision operations in Jacksonville with next-generation manufacturing, packaging and distribution capabilities, we are enhancing the resilience of our U.S. supply chain while helping more people see better and live better. This commitment reflects the confidence we have in our people, our technology, and our more than 40-year legacy of advancing eye health globally.”

Joaquin Duato, Chairman And Chief Executive Officer, Johnson & Johnson

“Johnson & Johnson’s commitment is a strong vote of confidence in Jacksonville, our workforce, and our future. Jacksonville continues to lead in advanced manufacturing and life sciences innovation. This expansion strengthens our high-tech footprint while creating quality jobs and long-term opportunities for our community.”

Donna Deegan, Mayor Of Jacksonville

“Florida continues to play a leading role in strengthening America’s healthcare supply chain to better serve patients. The billion-dollar investment in Jacksonville will help expand the domestic capacity and strengthen America’s healthcare infrastructure. That means more jobs in Florida, a stronger national economy, less reliance on foreign healthcare products, and better results for our nation’s long-term health and competitiveness.”

Rick Scott, U.S. Senator

“I am thrilled to see this major $1 billion investment in our state, funding new state of the art facilities and supporting jobs in the Jacksonville area. This is more than simple investment – this represents a down payment on the future of Jacksonville and the state of Florida. Companies are moving to Florida in droves, and massive investment such as this highlights Florida as the nation’s top state to grow your family and your business.”

Ashley Moody, U.S. Senator

“Johnson & Johnson’s continued investment in Jacksonville reflects the region’s strength in advanced manufacturing and critical healthcare production. It supports a skilled workforce, strengthens domestic capacity, and reinforces Northeast Florida’s role in keeping America economically competitive.”

John Rutherford, U.S. Representative

“Johnson & Johnson’s $1 billion investment in Jacksonville will strengthen the supply chain for critical vision products while creating high-quality jobs and generating significant economic benefits for Northeast Florida. The project reinforces Jacksonville’s status as a premier destination for healthcare manufacturing and innovation, helping ensure the region remains at the forefront of supporting patients and advancing medical technology.”

Aaron Bean, U.S. Representative

Source link

Gelatys Opens New $8 Million Production Facility, Expanding U.S. Manufacturing Capacity and Fueling National Grocery Growth

The #1 Gelato Frozen Novelties Brand in the U.S. Scales Production to Accelerate National Expansion

MIAMI, May 27, 2026 /PRNewswire/ — Gelatys, the #1 gelato frozen novelties brand in the United States and the only manufacturer of frozen gelato novelties in America, announced the opening of a new, state-of-the-art production facility in Fort Myers, FL. With an $8 million investment, the new 30,000+ square-foot facility is operational, signifying a key step in the company’s growth into a national CPG brand.

Gelatys CEO, Adolfo Heller Cohen, in front of the new production facility in Fort Myers, FL

Built on a 1.5-acre site, the Fort Myers facility investment represents more than a manufacturing expansion; it’s the operational foundation Gelatys is building to support national grocery growth, fuel differentiated frozen-novelty innovation, and solidify its position as the defining brand in a category it pioneered. The site features next-generation machinery capable of producing in one hour what previously required an entire day. It will scale production to support the national expansion of Mini Gems, Gelatys’ premium, portion-controlled gelato mini pops, and the next generation of premium Italian-style frozen novelty innovation.

“When my family and I moved to Miami, Gelatys began as a dream to bring true artisanal gelato to the U.S. market. We quickly saw a larger opportunity; premium gelato novelties were not being manufactured at scale because of how technically complex they are. That challenge became our innovation story, pushing us to create our own processes, adapt machinery, and build products that did not yet exist in the market,” said Adolfo Joel Heller Cohen, Founder & CEO, Gelatys. “Our new Fort Myers facility isn’t just an expansion, it’s the infrastructure we always knew this brand would need when growing from a local concept into a national brand. We’re the only manufacturer of its kind in the United States, and we built that from scratch. The ambition that started Gelatys hasn’t changed, and looking ahead, we’re just getting started.”

The new facility reflects the full scope of Gelatys’ growth trajectory. Since launching as a two-kiosk mall concept in Miami in 2016, the brand has expanded to 5,000+ locations across 26 states, with a retail footprint that includes Whole Foods Market, Sprouts, Wegmans, H-E-B, Kroger banners including Mariano’s, QFC, Fred Meyer and King Soopers, The Fresh Market, and more.

Besides its manufacturing significance, the Fort Myers facility is creating approximately 75 new jobs in the region, adding to the roughly 50 employees that supported Gelatys’ original Miami facility. This new operation is the production backbone of what Gelatys is building, an American-made frozen gelato novelties brand designed to scale.

For more information about Gelatys and Mini Gems, visit gelatys.com or follow @gelatysusa on Instagram.

Media Contact
Amy Tew
310-351-4332
[email protected]

SOURCE Gelatys

Source link

Gelatys Opens New $8 Million Production Facility, Expanding U.S. Manufacturing Capacity and Fueling National Grocery Growth

Gelatys Opens New $8 Million Production Facility, Expanding U.S. Manufacturing Capacity and Fueling National Grocery Growth

The #1 Gelato Frozen Novelties Brand in the U.S. Scales Production to Accelerate National Expansion

MIAMI, May 27, 2026 /PRNewswire/ — Gelatys, the #1 gelato frozen novelties brand in the United States and the only manufacturer of frozen gelato novelties in America, announced the opening of a new, state-of-the-art production facility in Fort Myers, FL. With an $8 million investment, the new 30,000+ square-foot facility is operational, signifying a key step in the company’s growth into a national CPG brand.

Built on a 1.5-acre site, the Fort Myers facility investment represents more than a manufacturing expansion; it’s the operational foundation Gelatys is building to support national grocery growth, fuel differentiated frozen-novelty innovation, and solidify its position as the defining brand in a category it pioneered. The site features next-generation machinery capable of producing in one hour what previously required an entire day. It will scale production to support the national expansion of Mini Gems, Gelatys’ premium, portion-controlled gelato mini pops, and the next generation of premium Italian-style frozen novelty innovation.

“When my family and I moved to Miami, Gelatys began as a dream to bring true artisanal gelato to the U.S. market. We quickly saw a larger opportunity; premium gelato novelties were not being manufactured at scale because of how technically complex they are. That challenge became our innovation story, pushing us to create our own processes, adapt machinery, and build products that did not yet exist in the market,” said Adolfo Joel Heller Cohen, Founder & CEO, Gelatys. “Our new Fort Myers facility isn’t just an expansion, it’s the infrastructure we always knew this brand would need when growing from a local concept into a national brand. We’re the only manufacturer of its kind in the United States, and we built that from scratch. The ambition that started Gelatys hasn’t changed, and looking ahead, we’re just getting started.”

The new facility reflects the full scope of Gelatys’ growth trajectory. Since launching as a two-kiosk mall concept in Miami in 2016, the brand has expanded to 5,000+ locations across 26 states, with a retail footprint that includes Whole Foods Market, Sprouts, Wegmans, H-E-B, Kroger banners including Mariano’s, QFC, Fred Meyer and King Soopers, The Fresh Market, and more.

Besides its manufacturing significance, the Fort Myers facility is creating approximately 75 new jobs in the region, adding to the roughly 50 employees that supported Gelatys’ original Miami facility. This new operation is the production backbone of what Gelatys is building, an American-made frozen gelato novelties brand designed to scale.

For more information about Gelatys and Mini Gems, visit gelatys.com or follow @gelatysusa on Instagram.

Media Contact
Amy Tew
310-351-4332
415099@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gelatys-opens-new-8-million-production-facility-expanding-us-manufacturing-capacity-and-fueling-national-grocery-growth-302782761.html

SOURCE Gelatys

Source link